secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-103150
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics announces 1-for-14 reverse stock split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Effective 5:00 p.m. ET on March 13, 2026; trading on split-adjusted basis starts March 16 under ticker XLO.
- Outstanding shares reduce from ~73.5M to ~5.2M; authorized shares and par value unchanged.
- Purpose is to increase per-share price to meet Nasdaq minimum $1.00 bid requirement.
- No fractional shares issued; stockholders receiving cash in lieu of fractional shares.
- Stockholders approved reverse split at Special Meeting held February 23, 2026; ratio set by Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/xlo-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-103150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer